Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence-Reference-Cited by-同舟云学术

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence

Published:2020-01-06 Issue:5 Volume:42 Page:828-838
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Ham Janneke C.¹^ORCID,Meerten Esther²,Fiets W. Edward³,Beerepoot Laurens V.⁴,Jeurissen Frank J. F.⁵,Slingerland Marije⁶,Jonker Marianne A.⁷,Husson Olga⁸⁹,Graaf Winette T. A.¹¹⁰,Herpen Carla M. L.¹

Affiliation:

1. Department of Medical Oncology Radboud University Medical Center Nijmegen HB The Netherlands

2. Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam GD The Netherlands

3. Department of Internal Medicine Medical Center Leeuwarden Leeuwarden AD The Netherlands

4. Department of Internal Medicine Elisabeth TweeSteden Hospital Tilburg AD The Netherlands

5. Department of Internal Medicine Medical Center Haaglanden The Hague VA The Netherlands

6. Department of Medical Oncology Leiden University Medical Center Leiden ZA The Netherlands

7. Biostatistics, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen HB The Netherlands

8. Department of Psychosocial Research and Epidemiology Netherlands Cancer Institute Amsterdam CX The Netherlands

9. Division of Clinical Studies Institute of Cancer Research London UK

10. Department of Medical Oncology Netherlands Cancer Institute Amsterdam CX The Netherlands

Funder

Merck KGaA

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26053

Reference24 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Management of Recurrent Head and Neck Cancer

3. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

4. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

5. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing recurrent/advanced oropharyngeal/oesophageal cancer with cetuximab-based regimens: A case series;F1000Research;2024-02-22

2. Synergistic Potential of Methotrexate and Gefitinib: A Promising Palliative Approach for Advanced and Recurrent Head and Neck Cancers;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024

3. Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review);Oncology Letters;2023-07-17

4. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

5. The Inconsistent Assessment of Quality of Life in Patients Treated for Head and Neck Cancer with Anti-EGFR Inhibitors: A Systematic Scoping Review;Cancers;2023-04-26